Party on: Base editing startup, computational drug discovery experts and CRO bag close to $2B total on their way to Nasdaq
On the back of Black Diamond Therapeutics’ roaring public debut, the IPO momentum is pushing three biotech players from very different corners of the industry to shiny listings on the Nasdaq.
Gene editing startup Beam Therapeutics, computational drug discovery specialist Schrödinger and contract research organization PPD have collectively bagged close to $2 billion by pricing at the top of or above the range laid out in their terms.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.